Aaron Block, BSc, MBA
Senior Director Business Development
Aaron holds a bachelor’s degree in neuroscience from The Pennsylvania State University, USA. After several years of research activity in the neuroscience field studying cognitive deficits in mouse models of Down Syndrome and managing multiple collaborations, he went on to obtain an MBA from Boston University, USA to transition into the biopharma industry. Aaron joined Theragnostics Ltd. in 2017 as junior analyst and subsequently worked his way up to Senior Director of Project Management and Business Development where he was responsible for helping lead the company through the FDA drug shortage program, receiving full FDA approval of Nephroscan™ and launching the product in the US market with its partner GE Healthcare.
Aaron joined Ariceum following the acquisition of Theragnostics in June 2023.